TLDR: Ultromics, a leader in AI-driven cardiology solutions, has successfully raised $55 million in Series C funding. This investment will fuel the expansion of their FDA-cleared EchoGo® platform, which utilizes artificial intelligence to enhance the early and accurate detection of complex heart conditions like Heart Failure with preserved Ejection Fraction (HFpEF) and cardiac amyloidosis from standard echocardiograms.
Oxford, UK – Ultromics, a pioneering company at the forefront of AI-driven cardiology solutions, announced today that it has secured $55 million in Series C financing. The funding round was co-led by prominent investors L&G, Allegis Capital, and Lightrock, with continued support from existing backers including Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. Additionally, major U.S. health systems, specifically UChicago Medicine’s venture investment vehicle, UCM Ventures, and UPMC Enterprises, participated in the round.
This significant capital injection is earmarked for expanding Ultromics’ operations and accelerating its research and development efforts. The company’s core offering, the FDA-cleared EchoGo® platform, leverages artificial intelligence to analyze standard echocardiograms, extracting hidden disease signals to enable earlier and more accurate detection of complex heart conditions. This innovative approach aims to address a critical diagnostic gap, particularly for elusive forms of heart failure such as Heart Failure with preserved Ejection Fraction (HFpEF) and cardiac amyloidosis, without requiring new hardware or disrupting existing clinical workflows.
Heart failure remains a growing global health crisis, with millions of patients undiagnosed, especially those with harder-to-detect forms. In the U.S. alone, heart failure accounts for over $30 billion in annual healthcare costs, a figure projected to exceed $70 billion by 2030. Up to 64% of HFpEF cases currently go undetected, and cardiac amyloidosis is frequently misdiagnosed, leading to delayed treatment and potential irreversible damage. Ultromics’ AI-driven technology directly tackles this challenge.
Built on extensive clinical studies and trained on hundreds of thousands of echo scans, the EchoGo® platform generates real-time probability scores, assisting cardiologists in identifying high-risk patients earlier than traditional methods. Ultromics has already analyzed over 430,000 echocardiograms to date. Clinical studies have demonstrated the efficacy of EchoGo®, with improvements in HFpEF detection by 73.6% compared to standard clinical risk scores. Furthermore, the company’s latest diagnostic model for cardiac amyloidosis, validated in a global study across 18 institutions, outperformed current clinical risk scores in distinguishing the disease from similar conditions.
Alastair Stewart, Head of Investments, Venture Capital, at L&G, commented on the investment, stating, ‘Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies. This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year.’
Also Read:
- Ambience Healthcare Achieves Unicorn Status with $243 Million Series C Funding, Valued at $1.25 Billion
- Venture Capital Fuels Expansion of AI Scribe Platforms in Healthcare
Ultromics has rapidly expanded its platform capabilities and U.S. market presence over the past year. In late 2024, the company received FDA Breakthrough Device clearance for EchoGo® Amyloidosis, followed in 2025 by the launch of EchoGo® Score, a new feature that adds AI-driven probability scoring to EchoGo® Heart Failure. The company is now expanding across the U.S. to integrate AI-enhanced diagnostics into routine cardiac care, aiming to make it a default step in the cardiac workup for hospitals and echo labs with high volumes of at-risk patients. Ultromics also plans to broaden its pipeline to include additional cardiac conditions, explore new distribution channels, and deepen partnerships with health systems and clinical leaders.
